Search Results

You are looking at 1 - 10 of 39 items for :

  • "papillary thyroid cancer" x
Clear All
Open access

Mubashir Mulla and Klaus-Martin Schulte

Introduction Papillary thyroid cancer (PTC) is the most common thyroid cancer. Metastases from PTC most commonly involve the cervical lymph nodes (CLNs). The incidence of CLN metastases (CLNM) is reported between 30 and 80% (1, 2) . Some studies

Open access

Marra Aghajani, Tara Roberts, Tao Yang, Charles McCafferty, Nicole Caixeiro, Paul DeSouza and Navin Niles

To date, no research evaluating the predictive capabilities of soluble programmed cell death-ligand 1 (sPD-L1) in thyroid cancer patients has been performed. We aimed to investigate the prognostic significance of sPD-L1 expression in papillary thyroid cancer (PTC), and to evaluate the association between sPD-L1 levels with tumoural PD-L1 expression and patient outcomes. Pre-treatment levels of serum and plasma sPD-L1 were measured by enzyme-linked immunosorbent assay (ELISA) in 101 PTC patients. Tissue microarrays were stained with an anti-PD-L1 antibody, clone SP263 (Ventana). The median serum sPD-L1 concentration in PTC patients was significantly higher compared to healthy controls (p=0.028). An increased incidence of extrathyroidal extension was significantly associated with an elevated serum sPD-L1 level (p=0.015). Patients with high serum sPD-L1 levels had significantly shorter median disease-free survival (DFS) as compared to those with low sPD-L1 levels (p=0.011). Following multivariate analysis, serum sPD-L1 was the only statistically significant predictor for DFS. Patients with both positive serum and tumoural PD-L1 expression had a significantly shorter DFS than those in any other subgroup (p=0.007). Our study is the first to confirm that sPD-L1 concentration is significantly associated with patient outcome in PTC. Soluble PD-L1 may provide clinicians with a non-invasive biomarker that can lessen dependence on tissue biopsies and diagnose aggressive thyroid cancers at a more treatable stage.

Open access

Marra Jai Aghajani, Tara Laurine Roberts, Tao Yang, Charles Eugenio McCafferty, Nicole J Caixeiro, Paul DeSouza and Navin Niles

To date, no research evaluating the predictive capabilities of soluble programmed cell death-ligand 1 (sPD-L1) in thyroid cancer patients has been performed. We aimed to investigate the prognostic significance of sPD-L1 expression in papillary thyroid cancer (PTC) and to evaluate the association between sPD-L1 levels with tumoural PD-L1 expression and patient outcomes. Pre-treatment levels of serum and plasma sPD-L1 were measured by ELISA in 101 PTC patients. Tissue microarrays were stained with an anti-PD-L1 antibody, clone SP263 (Ventana). The median serum sPD-L1 concentration in PTC patients was significantly higher compared to healthy controls (P = 0.028). An increased incidence of extrathyroidal extension was significantly associated with an elevated serum sPD-L1 level (P = 0.015). Patients with high serum sPD-L1 levels had significantly shorter median disease-free survival (DFS) as compared to those with low sPD-L1 levels (P = 0.011). Following multivariate analysis, serum sPD-L1 was the only statistically significant predictor for DFS. Patients with both positive serum and tumoural PD-L1 expression had a significantly shorter DFS than those in any other subgroup (P = 0.007). Our study is the first to confirm that sPD-L1 concentration is significantly associated with patient outcome in PTC. Soluble PD-L1 may provide clinicians with a non-invasive biomarker that can lessen dependence on tissue biopsies and diagnose aggressive thyroid cancers at a more treatable stage.

Open access

Norra Kwong, Ellen Marqusee, Michael S Gordon, P Reed Larsen, Jeffrey R Garber, Matthew I Kim and Erik K Alexander

low-risk papillary thyroid cancer . Lancet 2013 381 1046 – 1057 . ( doi:10.1016/S0140-6736(12)62205-3 ). 11 Mazzaferri EL . Papillary thyroid carcinoma: factors influencing prognosis and current therapy . Seminars in Oncology 1987 14

Open access

Marco Marino, Valentina Cirello, Valentina Gnarini, Carla Colombo, Elisa Pignatti, Livio Casarini, Chiara Diazzi, Vincenzo Rochira, Katia Cioni, Bruno Madeo, Cesare Carani, Manuela Simoni and Laura Fugazzola

statement M Marino and V Cirello contributed equally to this work. References 1 Romei C Fugazzola L Puxeddu E Frasca F Viola D Muzza M Moretti S Nicolosi ML Giani C Cirello V . Modifications in the papillary thyroid cancer gene

Open access

Changjiao Yan, Meiling Huang, Xin Li, Ting Wang and Rui Ling

Introduction Thyroid cancer, especially papillary subtype, is the most common malignancy in the endocrine system ( 1 ). Papillary thyroid cancer (PTC) can be further classified into conventional variant (CPTC), follicular variant (FVPTC) and

Open access

Barbora Pekova, Sarka Dvorakova, Vlasta Sykorova, Gabriela Vacinova, Eliska Vaclavikova, Jitka Moravcova, Rami Katra, Petr Vlcek, Pavla Sykorova, Daniela Kodetova, Josef Vcelak and Bela Bendlova

malignancy is higher in pediatric nodules compared with adults, 26 vs 7–15% ( 2 , 4 ). Pediatric thyroid cancer is a rare disease occurring mostly in females than in males ( 1 ). The most common type is papillary thyroid cancer (PTC), which represents 90

Open access

Dario de Biase, Federica Torricelli, Moira Ragazzi, Benedetta Donati, Elisabetta Kuhn, Michela Visani, Giorgia Acquaviva, Annalisa Pession, Giovanni Tallini, Simonetta Piana and Alessia Ciarrocchi

die within 1 year from diagnosis. Well-differentiated papillary thyroid cancers (PTCs) are considered indolent tumors, with slow rate of growth, low metastatic potential and excellent prognosis (10-year patient survival rate up to 95%) ( 4 , 5

Open access

Guoquan Zhu, Yuying Deng, Liqin Pan, Wei Ouyang, Huijuan Feng, Juqing Wu, Pan Chen, Jing Wang, Yanying Chen and Jiaxin Luo

Introduction Papillary thyroid cancer (PTC) is a common endocrine malignancy, accounting for approximately 90% of all thyroid cancers. There are several histological variants of PTC, with conventional PTC constituting the majority of cases ( 1

Open access

M L Gild, M Bullock, C K Pon, B G Robinson and R J Clifton-Bligh

-AAG reduced papillary thyroid cancer 1 (PTC1) expression levels and increased radioiodine accumulation in PCCL3 thyroid cells where PTC1 was induced by doxycycline (14) . This was determined to be independent of the sodium iodide symporter (NIS) and